Future of Neuroscience Conference

Neurotranslation: Neurologists and Neuroscientists
Defining the Next Generation of CNS Therapies

9:00 – 9:20 a.m.
Introduction
Jeffrey D. Rothstein, MD, PhD, Johns Hopkins University

9:20 – 9:55 a.m.
What is Drug Discovery?
Alfred W. Sandrock, MD, PhD, Biogen Idec

9:55 – 10:30 a.m.
Building an Academic Translational Research Unit
Barbara Slusher, PhD, Johns Hopkins University

10:30 – 10:50 a.m.
Break and Posters

10:50 – 11:20 a.m.
Abstract Presentations
SC01.001 Impulsivity and Catechol-O-Methyltransferase Inhibition: A Translational Study Andrew Kayser

SC01.002 The Therapeutic Effects of RG3039 in Severe Spinal Muscular Atrophy Mice and Normal Human Volunteers James P. Van Meerbeke

11:20 – 11:55 a.m.
NIH, FDA and Drug Discovery
Walter Koroshetz, MD, FAAN, NIH/NINDS

11:55 AM – 12:30 p.m.
Drug Screening/IPS Stem Cells and Academic Small Molecule Discovery
Christopher Henderson, PhD, Columbia University

12:30 – 1:30 p.m.
Lunch

1:30 – 2:05 p.m.
Biomarkers: Multiple Sclerosis
Bibiana Bielekova, MD, NIH/NINDS

2:05 – 2:40 p.m.
Surrogate Markers: Alzheimer's and Imaging
Marilyn Albert, PhD, Johns Hopkins University

2:40 – 3:10 p.m.
Abstract Presentations
SC01.003 Suppression of RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis Michael Gurevich

Suppression of Experimental Autoimmune Encephalomyelitis with Nanoparticles Carrying a Central Nervous System Antigen and a Non-Toxic Aryl Hydrocarbon Receptor Ligand Ada Yeste

3:10 – 3:30 p.m.
Break and Posters

3:30 – 4:05 p.m.
Clinical Trials: Academic Translation and Clinical and Translational Science Awards
Justin McArthur, MBBS, MPH, FAAN, Johns Hopkins University

4:05 – 4:40 p.m.
Neurotherapeutics Discovery and Development in the Academic Setting: A New Paradigm
Michael Rogawski, MD, PhD, University of California, Davis

4:40 – 5:00 p.m.
Questions and Answers

---

Poster Presentations

Presentation Times: 10:30 – 10:50 a.m. and 3:10 – 3:30 p.m.

SC02.001 MCAM Identifies Encephalitogenic TH17 Lymphocytes and Promotes Their Recruitment to the CNS Catherine Larochelle

SC02.002 FcγReceptor Polymorphisms, Disease Severity and Response to IVIG Treatment in Myasthenia Gravis Carolina Barnett Tapia

SC02.003 DJ-1 Based Peptide as a Novel Neuroprotective Strategy for Parkinson's Disease Nirit Lev

SC02.004 Adeno-Associated Viral (AAV)-Mediated Follistatin (FS) Gene Transfer Toxicology Studies in Preparation for Phase I Clinical Trial Janaiah Kota

SC02.005 Using Pimonidazole Delineated Penumbra To Improve Translational Research on Acute Stroke Neuroprotection Fen-Lei Chang

SC02.006 Suppression of NF-?B Activation and Inflammation in Glial Cells by RNS60, a Novel Therapeutic: Implications for Neurodegenerative Disorders Saurabh Khasnavis

SC02.007 Treatment of Malignant Gliomas Using Thermally Targeted Peptide Therapeutics Gene L. Bidwell

SC02.008 Peptidyl-Prolyl Isomerase Pin1: A Common Therapeutic Target for Synaptic Dysfunction and Protein Misfolding in Alzheimer's Disease Frances Chow

SC02.009 Combined Quantitative MRI and Quantitative MRS May Improve Early Diagnosis of Alzheimer's Disease Thao T. Tran